{"id":"nicotinic-acid","rwe":[{"pmid":"41882411","year":"2026","title":"Comparative metabolome and metallomic analyses of three organs from Cistus creticus.","finding":"","journal":"Planta","studyType":"Clinical Study"},{"pmid":"41872243","year":"2026","title":"Effect of pH on niacinamide skin permeation.","finding":"","journal":"Scientific reports","studyType":"Clinical Study"},{"pmid":"41870365","year":"2026","title":"Structural characterization, proton conductivity and furfural catalysis of novel polyfunctional zirconium phosphonates.","finding":"","journal":"Dalton transactions (Cambridge, England : 2003)","studyType":"Clinical Study"},{"pmid":"41850071","year":"2026","title":"Impact of various types of heat treatment on the content of selected B vitamin and their profile in goose breast meat.","finding":"","journal":"Poultry science","studyType":"Clinical Study"},{"pmid":"41846319","year":"2026","title":"Metabolic characteristic changes in local tissues after high-intensity focused ultrasound treatment for uterine fibroids.","finding":"","journal":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","studyType":"Clinical Study"}],"_fda":{"id":"80eed639-4867-48e0-9848-f3b41e280cad","set_id":"ef7290e2-922b-4ef3-a60a-57a2c3577af8","openfda":{"nui":["N0000184306","N0000185371","N0000175629","M0000728","M0023708","M0006342","N0000175594","M0014839"],"upc":["0649818020383"],"unii":["7LP2MPO46S","7L3E358N9L","3E0I92Z2GR","4L6452S749","T42NAD2KHC","AE28F7PNPL","BR1SN1JS2W","0U46U6E8UK","2679MF687A","25X51I8RD4","68Y4CF58BV","TLM2976OFR","GKN429M9VS","EJ27X76M46","U6WSN5SQ1Z"],"route":["ORAL"],"spl_id":["80eed639-4867-48e0-9848-f3b41e280cad"],"brand_name":["Methylation Assist Liquescence"],"spl_set_id":["ef7290e2-922b-4ef3-a60a-57a2c3577af8"],"package_ndc":["83027-0095-1"],"product_ndc":["83027-0095"],"generic_name":["INOSITOL, METHYLCOBALAMIN (VITAMIN B12), NADIDUM (NADH), NIACIN (NICOTINIC ACID) , NICOTINAMIDUM (NIACINAMIDE), L-METHIONINE, PYRIDOXINUM HYDROCHLORICUM (VITAMIN B6), SAME (S-ADENOSYL METHIONINE), ZINCUM GLUCONICUM, MAGNESIUM GLUCONICUM DIHYDRICUM, RIBOFLAVINUM (VITAMIN B2), UBIDECARENONUM COQ10), DOPAMINE, SEROTONIN, EGG WHITE"],"product_type":["HUMAN OTC DRUG"],"pharm_class_cs":["Allergens [CS]","Egg Proteins, Dietary [CS]","Dietary Proteins [CS]","Nicotinic Acids [CS]"],"pharm_class_pe":["Cell-mediated Immunity [PE]","Increased Histamine Release [PE]"],"substance_name":["ADEMETIONINE","DOPAMINE HYDROCHLORIDE","EGG WHITE","INOSITOL","MAGNESIUM GLUCONATE","METHIONINE","METHYLCOBALAMIN","NADIDE","NIACIN","NIACINAMIDE","PYRIDOXINE HYDROCHLORIDE","RIBOFLAVIN","SEROTONIN HYDROCHLORIDE","UBIDECARENONE","ZINC GLUCONATE"],"pharm_class_epc":["Non-Standardized Food Allergenic Extract [EPC]","Nicotinic Acid [EPC]"],"manufacturer_name":["Nutritional Specialties, Inc."],"is_original_packager":[true]},"purpose":["PURPOSE: Provides potentized homeo-nutritional support for the body's natural ability to methylate properly.† †Claims based on traditional homeopathic practice, not accepted medical evidence. Not FDA evaluated."],"version":"1","warnings":["WARNINGS: Professional Use Only If pregnant or breast-feeding, ask a health professional before use. In case of overdose, get medical help or contact a Poison Control Center right away. If condition worsens, seek medical attention. KEEP OUT OF REACH OF CHILDREN Do not use if tamper evident seal is broken or missing. Store in a cool place after opening"],"questions":["QUESTIONS: MANUFACTURED EXCLUSIVELY FOR NUTRITIONAL SPECIALTIES, INC. PO BOX 97227 PITTSBURG, PA 15229 www.phpltd.com"],"effective_time":"20230814","active_ingredient":["ACTIVE INGREDIENTS: Inositol 6X, 12X, Methylcobalamin (Vitamin B12) 6X, 12X, Nadidum (NADH) 6X, 12X, Niacin (Nicotinic Acid) 6X, 12X, Nicotinamidum (Niacinamide) 6X, 12X, L-Methionine 6X, 12X, Pyridoxinum Hydrochloricum (Vitamin B6) 6X, 12X, SAMe (S-Adenosyl Methionine) 6X, 12X, Zincum Gluconicum 6X, 12X, Magnesium Gluconicum Dihydricum 8X, 12X, Riboflavinum (Vitamin B2) 8X, 12X, Ubidecarenonum CoQ10) 8X, 12X, Dopamine 12X, Serotonin 12X, Egg White 15C, 30C."],"inactive_ingredient":["INACTIVE INGREDIENTS: Alcohol USP 20%, Purified Water USP."],"indications_and_usage":["INDICATIONS: Provides potentized homeo-nutritional support for the body's natural ability to methylate properly.† †Claims based on traditional homeopathic practice, not accepted medical evidence. Not FDA evaluated."],"dosage_and_administration":["DIRECTIONS: Adults 1 to 2 teaspoons one to two times daily. Children under twelve one half adult dosage. Consult a physician for use in children under 12 years of age."],"spl_product_data_elements":["Methylation Assist Liquescence Inositol, Methylcobalamin (Vitamin B12), Nadidum (NADH), Niacin (Nicotinic Acid) , Nicotinamidum (Niacinamide), L-Methionine, Pyridoxinum Hydrochloricum (Vitamin B6), SAMe (S-Adenosyl Methionine), Zincum Gluconicum, Magnesium Gluconicum Dihydricum, Riboflavinum (Vitamin B2), Ubidecarenonum CoQ10), Dopamine, Serotonin, Egg White INOSITOL INOSITOL METHYLCOBALAMIN METHYLCOBALAMIN NADIDE NADIDE NIACIN NIACIN NIACINAMIDE NIACINAMIDE METHIONINE METHIONINE PYRIDOXINE HYDROCHLORIDE PYRIDOXINE ADEMETIONINE ADEMETIONINE ZINC GLUCONATE ZINC CATION MAGNESIUM GLUCONATE MAGNESIUM CATION RIBOFLAVIN RIBOFLAVIN UBIDECARENONE UBIDECARENONE DOPAMINE HYDROCHLORIDE DOPAMINE SEROTONIN HYDROCHLORIDE SEROTONIN EGG WHITE EGG WHITE WATER ALCOHOL"],"keep_out_of_reach_of_children":["KEEP OUT OF REACH OF CHILDREN: In case of overdose, get medical help or contact a Poison Control Center right away."],"package_label_principal_display_panel":["PACKAGE LABEL DISPLAY: METHYLGENETIC NUTRITION HOMEOPATHIC NDC 83027-0095-1 METHYLATION ASSIST LIQUESCENCE 4 FL. OZ (120 ml) METHYLATION ASSIST LIQUESCENCE"]},"tags":[{"label":"Nicotinic Acid","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Hydroxycarboxylic acid receptor 2","category":"target"},{"label":"HCAR2","category":"gene"},{"label":"HCAR3","category":"gene"},{"label":"APP","category":"gene"},{"label":"C04AC01","category":"atc"},{"label":"Topical","category":"route"},{"label":"Oral","category":"route"},{"label":"Capsule","category":"form"},{"label":"Shampoo","category":"form"},{"label":"Solution","category":"form"},{"label":"Tablet","category":"form"},{"label":"Active","category":"status"},{"label":"Familial hypercholesterolemia - heterozygous","category":"indication"},{"label":"Hypercholesterolemia","category":"indication"},{"label":"Hyperlipidemia","category":"indication"},{"label":"Hypertriglyceridemia","category":"indication"},{"label":"Mixed hyperlipidemia","category":"indication"},{"label":"Vitamin deficiency","category":"indication"},{"label":"Medpointe Pharm Hlc","category":"company"},{"label":"Approved 1950s","category":"decade"},{"label":"Antimetabolites","category":"pharmacology"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Hypolipidemic Agents","category":"pharmacology"},{"label":"Lipid Regulating Agents","category":"pharmacology"},{"label":"Micronutrients","category":"pharmacology"},{"label":"Vasodilator Agents","category":"pharmacology"},{"label":"Vitamin B Complex","category":"pharmacology"},{"label":"Vitamins","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"llr":1022.336,"date":"","count":869,"signal":"Flushing","source":"DrugCentral FAERS","actionTaken":"Reported 869 times (LLR=1022)"},{"llr":282.215,"date":"","count":535,"signal":"Off label use","source":"DrugCentral FAERS","actionTaken":"Reported 535 times (LLR=282)"},{"llr":228.839,"date":"","count":124,"signal":"Product residue present","source":"DrugCentral FAERS","actionTaken":"Reported 124 times (LLR=229)"},{"llr":215.018,"date":"","count":17,"signal":"Contraindicated product administered","source":"DrugCentral FAERS","actionTaken":"Reported 17 times (LLR=215)"},{"llr":200.888,"date":"","count":3,"signal":"Pemphigus","source":"DrugCentral FAERS","actionTaken":"Reported 3 times (LLR=201)"},{"llr":198.055,"date":"","count":6,"signal":"Synovitis","source":"DrugCentral FAERS","actionTaken":"Reported 6 times (LLR=198)"},{"llr":194.191,"date":"","count":51,"signal":"Product use in unapproved indication","source":"DrugCentral FAERS","actionTaken":"Reported 51 times (LLR=194)"},{"llr":173.17,"date":"","count":3,"signal":"Hand deformity","source":"DrugCentral FAERS","actionTaken":"Reported 3 times (LLR=173)"},{"llr":173.035,"date":"","count":23,"signal":"Completed suicide","source":"DrugCentral FAERS","actionTaken":"Reported 23 times (LLR=173)"},{"llr":169.062,"date":"","count":37,"signal":"Treatment failure","source":"DrugCentral FAERS","actionTaken":"Reported 37 times (LLR=169)"},{"llr":163.095,"date":"","count":25,"signal":"Systemic lupus erythematosus","source":"DrugCentral FAERS","actionTaken":"Reported 25 times (LLR=163)"},{"llr":157.327,"date":"","count":76,"signal":"Infusion related reaction","source":"DrugCentral FAERS","actionTaken":"Reported 76 times (LLR=157)"},{"llr":152.087,"date":"","count":156,"signal":"Toxicity to various agents","source":"DrugCentral FAERS","actionTaken":"Reported 156 times (LLR=152)"},{"llr":145.902,"date":"","count":7,"signal":"Drug abuse","source":"DrugCentral FAERS","actionTaken":"Reported 7 times (LLR=146)"},{"llr":143.883,"date":"","count":73,"signal":"Product use issue","source":"DrugCentral FAERS","actionTaken":"Reported 73 times (LLR=144)"}],"drugInteractions":[{"url":"/drug/pravastatin","drug":"pravastatin","action":"Monitor closely","effect":"May interact with Niacin, Pravastatin","source":"DrugCentral","drugSlug":"pravastatin"},{"url":"/drug/simvastatin","drug":"simvastatin","action":"Monitor closely","effect":"May interact with Niacin, Simvastatin","source":"DrugCentral","drugSlug":"simvastatin"}],"commonSideEffects":[{"effect":"Flushing","drugRate":"88%","severity":"common","organSystem":""},{"effect":"Diarrhea","drugRate":"","severity":"common","organSystem":""},{"effect":"Nausea","drugRate":"","severity":"common","organSystem":""},{"effect":"Vomiting","drugRate":"","severity":"common","organSystem":""},{"effect":"Increased cough","drugRate":"","severity":"common","organSystem":""},{"effect":"Pruritus","drugRate":"","severity":"common","organSystem":""},{"effect":"Rash","drugRate":"2%","severity":"common","organSystem":""},{"effect":"Dizziness","drugRate":"","severity":"common","organSystem":""},{"effect":"Tachycardia","drugRate":"","severity":"common","organSystem":""},{"effect":"Palpitations","drugRate":"","severity":"common","organSystem":""},{"effect":"Shortness of breath","drugRate":"","severity":"common","organSystem":""},{"effect":"Sweating","drugRate":"","severity":"common","organSystem":""},{"effect":"Burning sensation/skin burning sensation","drugRate":"","severity":"common","organSystem":""},{"effect":"Chills","drugRate":"","severity":"common","organSystem":""},{"effect":"Edema","drugRate":"","severity":"common","organSystem":""},{"effect":"Blood glucose increased","drugRate":"6.4%","severity":"common","organSystem":""}],"specialPopulations":{"Pregnancy":"Pregnancy Category C. Animal reproduction studies have not been conducted with nicotinic acid. It is also not known whether nicotinic acid at doses typically used for lipid disorders can cause fetal harm when administered to pregnant women or whether it can affect reproductive capacity. If woman receiving nicotinic acid for primary hypercholesterolemia (Types IIa or IIb) becomes pregnant, the drug should be discontinued. If woman being treated with nicotinic acid for hypertriglyceride","Geriatric use":"Of 979 patients in clinical studies of niacin, 21% of the patients were age 65 and over. No overall differences in safety and effectiveness were observed between these patients and younger patients, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.","Paediatric use":"Safety and effectiveness in children and adolescents have not been established.","Renal impairment":"Niacin extended-release tablets should be used with caution in patients with renal impairment.","Hepatic impairment":"Niacin extended-release tablets are contraindicated in active liver disease or significant or unexplained hepatic dysfunction or unexplained elevations of serum transaminases."},"seriousAdverseEvents":[{"effect":"Syncope","drugRate":"","severity":"serious"},{"effect":"Rhabdomyolysis","drugRate":"0.2%","severity":"serious"},{"effect":"Diabetes mellitus","drugRate":"3.6%","severity":"serious"}]},"trials":[],"aliases":["Tredaptive","Niacin","Niacin 500 (Jamp Pharma) NPN 00557412","niacin"],"company":"Medpointe Pharm Hlc","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Nicotinic Acid","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:09:01.321387+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:09:07.519150+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Nicotinic Acid","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:09:07.810490+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:09:00.047422+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:09:00.047487+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:09:15.317791+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:09:00.047493+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL573/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:09:08.899702+00:00"}},"allNames":"niaspan","offLabel":[],"synonyms":["niacin potassium","niacin magnesium","nicotinic acid","vitamin b3 (niacin)","3-pyridinecarboxylic acid","niaspan","niacin","niacor","Vitamin B3"],"timeline":[{"date":"1957-07-24","type":"positive","source":"DrugCentral","milestone":"FDA approval (Medpointe Pharm Hlc)"}],"approvals":[{"date":"1957-07-24","orphan":false,"company":"MEDPOINTE PHARM HLC","regulator":"FDA"}],"brandName":"Niaspan","ecosystem":[{"indication":"Familial hypercholesterolemia - heterozygous","otherDrugs":[{"name":"alirocumab","slug":"alirocumab","company":"Sanofi Aventis"},{"name":"atorvastatin","slug":"atorvastatin","company":"Pfizer"},{"name":"bempedoic acid","slug":"bempedoic-acid","company":"Esperion Theraps Inc"},{"name":"choline fenofibrate","slug":"choline-fenofibrate","company":"Abbvie"}],"globalPrevalence":390000000},{"indication":"Hypercholesterolemia","otherDrugs":[{"name":"alirocumab","slug":"alirocumab","company":"Sanofi Aventis"},{"name":"atorvastatin","slug":"atorvastatin","company":"Pfizer"},{"name":"cerivastatin","slug":"cerivastatin","company":"Bayer Pharms"},{"name":"cholestyramine","slug":"cholestyramine","company":"Bristol Myers"}],"globalPrevalence":390000000},{"indication":"Hyperlipidemia","otherDrugs":[{"name":"cholestyramine","slug":"cholestyramine","company":"Bristol Myers"},{"name":"choline fenofibrate","slug":"choline-fenofibrate","company":"Abbvie"},{"name":"clofibrate","slug":"clofibrate","company":""},{"name":"colestipol","slug":"colestipol","company":"Pharmacia And Upjohn"}],"globalPrevalence":390000000},{"indication":"Hypertriglyceridemia","otherDrugs":[{"name":"atorvastatin","slug":"atorvastatin","company":"Pfizer"},{"name":"choline fenofibrate","slug":"choline-fenofibrate","company":"Abbvie"},{"name":"fenofibrate","slug":"fenofibrate","company":"Abbvie"},{"name":"gemfibrozil","slug":"gemfibrozil","company":"Pfizer Pharms"}],"globalPrevalence":1680000000},{"indication":"Mixed hyperlipidemia","otherDrugs":[{"name":"atorvastatin","slug":"atorvastatin","company":"Pfizer"},{"name":"cerivastatin","slug":"cerivastatin","company":"Bayer Pharms"},{"name":"choline fenofibrate","slug":"choline-fenofibrate","company":"Abbvie"},{"name":"ezetimibe","slug":"ezetimibe","company":"Msd Intl Gmbh"}],"globalPrevalence":390000000},{"indication":"Vitamin deficiency","otherDrugs":[{"name":"colecalciferol","slug":"colecalciferol","company":"Sandoz"},{"name":"cyanocobalamin","slug":"cyanocobalamin","company":""},{"name":"ergocalciferol","slug":"ergocalciferol","company":"Sanofi Aventis Us"},{"name":"ferrous sulfate","slug":"ferrous-sulfate","company":"Lederle"}],"globalPrevalence":null}],"mechanism":{"target":"Hydroxycarboxylic acid receptor 2","novelty":"Follow-on","targets":[{"gene":"HCAR2","source":"DrugCentral","target":"Hydroxycarboxylic acid receptor 2","protein":"Hydroxycarboxylic acid receptor 2"},{"gene":"HCAR3","source":"DrugCentral","target":"Hydroxycarboxylic acid receptor 3","protein":"Hydroxycarboxylic acid receptor 3"},{"gene":"APP","source":"DrugCentral","target":"Amyloid beta A4 protein","protein":"Amyloid beta A4 protein"},{"gene":"NNMT","source":"DrugCentral","target":"Nicotinamide N-methyltransferase","protein":"Nicotinamide N-methyltransferase"},{"gene":"NAMPT","source":"DrugCentral","target":"Nicotinamide phosphoribosyltransferase","protein":"Nicotinamide phosphoribosyltransferase"},{"gene":"QPRT","source":"DrugCentral","target":"Nicotinate-nucleotide pyrophosphorylase [carboxylating]","protein":"Nicotinate-nucleotide pyrophosphorylase [carboxylating]"}],"modality":"Small Molecule","drugClass":"Non-Standardized Food Allergenic Extract [EPC]","explanation":"","oneSentence":"","technicalDetail":"Niaspan exerts its effects by activating the GPR109A receptor, a subtype of the hydroxycarboxylic acid receptor 2, which is involved in the regulation of lipid metabolism and energy homeostasis."},"commercial":{"launchDate":"1957","_launchSource":"DrugCentral (FDA 1957-07-24, MEDPOINTE PHARM HLC)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2835","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=Nicotinic%20Acid","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Nicotinic Acid","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T12:57:16.130972","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T00:09:15.450566+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"inositol nicotinate","drugSlug":"inositol-nicotinate","fdaApproval":"","relationship":"same-class"}],"genericName":"nicotinic acid","indications":{"approved":[{"id":"nicotinic-acid-methylation-support","name":"Methylation support","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Not specified","pivotalTrial":null,"restrictions":[],"patientPopulation":"Not specified","diagnosticRequired":null,"brandNameForIndication":"Niaspan"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"inositol-nicotinate","brandName":"inositol nicotinate","genericName":"inositol nicotinate","approvalYear":"","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT01303341","phase":"PHASE1","title":"Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-02-18","conditions":["Advanced Malignant Solid Neoplasm","Recurrent Melanoma","Refractory Malignant Solid Neoplasm","Stage III Cutaneous Melanoma AJCC v7","Stage IIIA Cutaneous Melanoma AJCC v7","Stage IIIB Cutaneous Melanoma AJCC v7","Stage IIIC Cutaneous Melanoma AJCC v7","Stage IV Cutaneous Melanoma AJCC v6 and v7"],"enrollment":35,"completionDate":"2026-09-17"},{"nctId":"NCT06044935","phase":"NA","title":"Effect of Nicotinamide Riboside on Ketosis, Fat Oxidation & Metabolic Rate","status":"RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2024-01-08","conditions":["Overweight","Obesity"],"enrollment":100,"completionDate":"2028-01-31"},{"nctId":"NCT01861314","phase":"PHASE1","title":"Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-07-03","conditions":["Acute Myeloid Leukemia","Acute Myeloid Leukemia Post Cytotoxic Therapy","Recurrent Adult Acute Myeloid Leukemia","Secondary Acute Myeloid Leukemia"],"enrollment":15,"completionDate":"2027-03-19"},{"nctId":"NCT04430517","phase":"EARLY_PHASE1","title":"Effects of Nicotinamide Riboside on Bioenergetics and Oxidative Stress in Mild Cognitive Impairment/Alzheimer's Dementia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mclean Hospital","startDate":"2022-03-02","conditions":["Mild Cognitive Impairment","Mild Alzheimer Disease"],"enrollment":50,"completionDate":"2026-05-15"},{"nctId":"NCT02298348","phase":"PHASE1","title":"Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"New Approaches to Neuroblastoma Therapy Consortium","startDate":"2015-10-08","conditions":["Neuroblastoma"],"enrollment":18,"completionDate":"2026-12"},{"nctId":"NCT06587945","phase":"PHASE4","title":"Nicotinamide Riboside Oral Supplementation in Macula Off Retinal Detachment","status":"RECRUITING","sponsor":"Center for Eye Research Australia","startDate":"2025-09-19","conditions":["Retinal Detachment"],"enrollment":144,"completionDate":"2028-03-30"},{"nctId":"NCT07463651","phase":"PHASE3","title":"MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2026-05-01","conditions":["Acute Myeloid Leukemia (AML)","FLT3-ITD Mutation","Allogeneic Hematopoietic Cell Transplantation (HCT)","Maintenance Therapy","Gilteritinib","Sorafenib"],"enrollment":594,"completionDate":"2030-03-31"},{"nctId":"NCT03298451","phase":"PHASE3","title":"Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2017-10-11","conditions":["Hepatocellular Carcinoma"],"enrollment":1324,"completionDate":"2026-08-27"},{"nctId":"NCT05702398","phase":"EARLY_PHASE1","title":"Pilot Trial of Supplemental Vitamin A and Nicotinamide","status":"RECRUITING","sponsor":"Rhode Island Hospital","startDate":"2023-04-01","conditions":["Skin Cancer","Kidney Transplant Recipients"],"enrollment":30,"completionDate":"2028-03-01"},{"nctId":"NCT04614714","phase":"PHASE2,PHASE3","title":"Milk Volume Outcomes Following Oral Nicotinamide Riboside Supplementation in Mothers of Extremely Preterm Infants","status":"NOT_YET_RECRUITING","sponsor":"University of California, Davis","startDate":"2026-04-01","conditions":["Preterm Birth","Inadequate Milk Production"],"enrollment":40,"completionDate":"2027-12-31"},{"nctId":"NCT06309485","phase":"PHASE2","title":"Phase 2 Study of WGI-0301 for Advanced HCC","status":"RECRUITING","sponsor":"Zhejiang Haichang Biotech Co., Ltd.","startDate":"2024-07-31","conditions":["Advanced Hepatocellular Carcinoma (HCC)"],"enrollment":60,"completionDate":"2027-03"},{"nctId":"NCT04720716","phase":"PHASE3","title":"A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2021-02-07","conditions":["Hepatocellular Carcinoma"],"enrollment":344,"completionDate":"2025-12-31"},{"nctId":"NCT07475208","phase":"NA","title":"NR and Exercise for Blood Pressure","status":"NOT_YET_RECRUITING","sponsor":"ZHANG Jiaqi","startDate":"2026-04","conditions":["Hypertension (HTN)"],"enrollment":112,"completionDate":"2027-12"},{"nctId":"NCT07344636","phase":"NA","title":"Effects of NR Supplementation on Metabolic Flexibility in Zone 2 Training","status":"RECRUITING","sponsor":"ZHANG Jiaqi","startDate":"2026-01-06","conditions":["Health Adult Subjects"],"enrollment":16,"completionDate":"2027-07"},{"nctId":"NCT06345443","phase":"NA","title":"NRM on Vascular Perfusion in Healthy Adults","status":"ENROLLING_BY_INVITATION","sponsor":"Mayo Clinic","startDate":"2024-11-25","conditions":["Vascular Stiffness"],"enrollment":200,"completionDate":"2026-12-31"},{"nctId":"NCT07477275","phase":"NA","title":"Combination of Oral and Topical Whitening Agents for Reducing Skin Pigmentation","status":"ACTIVE_NOT_RECRUITING","sponsor":"USMARI Research & Innovation Centre","startDate":"2024-12-01","conditions":["Dark Spots"],"enrollment":68,"completionDate":"2026-04-30"},{"nctId":"NCT06900998","phase":"PHASE2","title":"Pilot Study: Effects of Nimodipine on Alcohol Drinking","status":"NOT_YET_RECRUITING","sponsor":"Yale University","startDate":"2026-09-01","conditions":["Alcohol Use Disorder"],"enrollment":5,"completionDate":"2032-06-30"},{"nctId":"NCT07475546","phase":"PHASE3","title":"Combination Gerotherapeutic Interventions for Healthspan Improvement","status":"ACTIVE_NOT_RECRUITING","sponsor":"AgelessRx","startDate":"2025-07-23","conditions":["Healthspan Improvement","Aging","Longevity"],"enrollment":30,"completionDate":"2026-04"},{"nctId":"NCT05468359","phase":"PHASE1,PHASE2","title":"Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2022-11-07","conditions":["Refractory Solid Tumor","Hepatocellular Carcinoma","Malignant Solid Tumor","Pediatric Cancer","Pediatric Solid Tumor","Fibrolamellar Carcinoma"],"enrollment":64,"completionDate":"2037-06"},{"nctId":"NCT06579209","phase":"NA","title":"NAD+ Oral Supplement Pilot Intervention in Adult Females","status":"COMPLETED","sponsor":"University of Rhode Island","startDate":"2024-12-01","conditions":["Cognitive Change","Inflammation","Neurodegenerative Diseases"],"enrollment":53,"completionDate":"2026-02-20"},{"nctId":"NCT06534944","phase":"PHASE1,PHASE2","title":"NAD Supplementation and Vascular Health in PAD","status":"COMPLETED","sponsor":"University of Oklahoma","startDate":"2023-02-27","conditions":["Peripheral Artery Disease"],"enrollment":8,"completionDate":"2024-12-30"},{"nctId":"NCT06787430","phase":"PHASE4","title":"Effects of Nicorandil on Microvascular Dysfunction in Patients With STEMI Undergoing Primary PCI","status":"NOT_YET_RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2026-03-01","conditions":["STEMI - ST-segment Elevation Myocardial Infarction"],"enrollment":170,"completionDate":"2027-12-31"},{"nctId":"NCT07468175","phase":"NA","title":"A 16-week Clinical Study Investigating a Dark Spot Corrector Serum in Women With Moderate Discrete Hyperpigmentation","status":"COMPLETED","sponsor":"Revision Skincare","startDate":"2024-10-21","conditions":["Hyperpigmentation","Dark Spots"],"enrollment":48,"completionDate":"2025-03-27"},{"nctId":"NCT04192136","phase":"NA","title":"NAD+ and Exercise in FA","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"2020-09-03","conditions":["Friedreich Ataxia 1"],"enrollment":75,"completionDate":"2025-10-31"},{"nctId":"NCT04571008","phase":"NA","title":"Effect of NMN Supplementation on Organ System Biology","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2020-10-01","conditions":["Glucose Metabolism Disorders"],"enrollment":56,"completionDate":"2025-03-04"},{"nctId":"NCT00939627","phase":"PHASE2","title":"Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-07","conditions":["Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma","Recurrent Metastatic Squamous Neck Cancer With Occult Primary","Recurrent Salivary Gland Cancer","Recurrent Squamous Cell Carcinoma of the Hypopharynx","Recurrent Squamous Cell Carcinoma of the Larynx","Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity","Recurrent Squamous Cell Carcinoma of the Nasopharynx","Recurrent Squamous Cell Carcinoma of the Oropharynx","Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Recurrent Verrucous Carcinoma of the Larynx","Recurrent Verrucous Carcinoma of the Oral Cavity","Salivary Gland Squamous Cell Carcinoma","Stage IV Squamous Cell Carcinoma of the Hypopharynx","Stage IV Squamous Cell Carcinoma of the Nasopharynx","Stage IVA Salivary Gland Cancer","Stage IVA Squamous Cell Carcinoma of the Larynx","Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IVA Squamous Cell Carcinoma of the Oropharynx","Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IVA Verrucous Carcinoma of the Larynx","Stage IVA Verrucous Carcinoma of the Oral Cavity","Stage IVB Salivary Gland Cancer","Stage IVB Squamous Cell Carcinoma of the Larynx","Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IVB Squamous Cell Carcinoma of the Oropharynx","Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IVB Verrucous Carcinoma of the Larynx","Stage IVB Verrucous Carcinoma of the Oral Cavity","Stage IVC Salivary Gland Cancer","Stage IVC Squamous Cell Carcinoma of the Larynx","Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IVC Squamous Cell Carcinoma of the Oropharynx","Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IVC Verrucous Carcinoma of the Larynx","Stage IVC Verrucous Carcinoma of the Oral Cavity","Tongue Cancer","Untreated Metastatic Squamous Neck Cancer With Occult Primary"],"enrollment":55,"completionDate":"2014-01"},{"nctId":"NCT05986123","phase":"NA","title":"Safety and Efficacy of Topical Cream for Post-inflammatory Hyperpigmentation Skin Among Malaysians","status":"COMPLETED","sponsor":"USMARI Research & Innovation Centre","startDate":"2023-11-01","conditions":["Healthy"],"enrollment":25,"completionDate":"2026-01-30"},{"nctId":"NCT07451496","phase":"NA","title":"PRecision gerOMedicinE: Tailored Healthy agEing With Lifestyle, sUpplements and drugS (PROMETHEUS)","status":"RECRUITING","sponsor":"National University of Singapore","startDate":"2025-09-29","conditions":["Ageing"],"enrollment":20,"completionDate":"2026-06-30"},{"nctId":"NCT06760533","phase":"EARLY_PHASE1","title":"Psilocybin-Assisted Psychotherapy in Treating Irritable Bowel Syndrome (IBS)","status":"NOT_YET_RECRUITING","sponsor":"NYU Langone Health","startDate":"2026-08","conditions":["IBS - Irritable Bowel Syndrome"],"enrollment":10,"completionDate":"2026-12"},{"nctId":"NCT06582706","phase":"PHASE1,PHASE2","title":"Nicotinic Acid for the Treatment of Alzheimer's Disease","status":"RECRUITING","sponsor":"Indiana University","startDate":"2024-12-19","conditions":["Alzheimer Disease"],"enrollment":30,"completionDate":"2026-12"},{"nctId":"NCT06200155","phase":"PHASE2","title":"Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-04-16","conditions":["Depression, Anxiety","Psilocybin-Assisted Psychotherapy","Advanced Cancer"],"enrollment":30,"completionDate":"2026-12-31"},{"nctId":"NCT02185560","phase":"","title":"Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2014-06-27","conditions":["Thyroid Carcinoma"],"enrollment":453,"completionDate":"2026-09-30"},{"nctId":"NCT02184416","phase":"","title":"Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With Sutent In 1st Line In The Real Life Setting","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-10-31","conditions":["Metastatic Renal Cell Carcinoma (mRCC)"],"enrollment":554,"completionDate":"2022-09-30"},{"nctId":"NCT07428889","phase":"NA","title":"Nicotinamide Adenine Dinucleotide Responses to a Nutritional Supplement","status":"RECRUITING","sponsor":"Shaklee Corporation","startDate":"2026-02","conditions":["Healthy Adult"],"enrollment":34,"completionDate":"2026-06"},{"nctId":"NCT01946529","phase":"PHASE2","title":"Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-12-27","conditions":["Desmoplastic Small Round Cell Tumor","Ewing Sarcoma of Bone or Soft Tissue","Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor","Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor"],"enrollment":24,"completionDate":"2026-07"},{"nctId":"NCT07144527","phase":"NA","title":"Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older Adults","status":"RECRUITING","sponsor":"Scott Silveira","startDate":"2026-02-21","conditions":["Aging","Frailty","Exercise Tolerance","Healthy Male and Female Subjects"],"enrollment":40,"completionDate":"2027-01-01"},{"nctId":"NCT02559778","phase":"PHASE2","title":"Pediatric Precision Laboratory Advanced Neuroblastoma Therapy","status":"RECRUITING","sponsor":"Giselle Sholler","startDate":"2015-09","conditions":["Neuroblastoma"],"enrollment":500,"completionDate":"2035-09"},{"nctId":"NCT07245979","phase":"NA","title":"Supplementation With Sirtuin Activators in Women With Increased Body Weight","status":"RECRUITING","sponsor":"Poznan University of Life Sciences","startDate":"2025-10-08","conditions":["Obesity & Overweight"],"enrollment":120,"completionDate":"2027-03-01"},{"nctId":"NCT07286318","phase":"EARLY_PHASE1","title":"A Randomized Controlled Trial of Topical 5% Niacinamide for Skin Cancer Prevention in Transplant Recipients","status":"NOT_YET_RECRUITING","sponsor":"Marissa Lobl","startDate":"2026-03-01","conditions":["Skin Cancer","Cutaneous Squamous Cell Carcinoma (CSCC)","Actinic Keratosis (AK)","Organ Transplant Recipient"],"enrollment":20,"completionDate":"2027-06-30"},{"nctId":"NCT04039607","phase":"PHASE3","title":"A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2019-09-30","conditions":["Hepatocellular Carcinoma"],"enrollment":732,"completionDate":"2026-11-09"},{"nctId":"NCT07013591","phase":"PHASE2","title":"Nicotinamide Mononucleotide in Patients Undergoing CABG Surgery","status":"NOT_YET_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2026-03-31","conditions":["Coronary Artery Bypass Graft"],"enrollment":90,"completionDate":"2029-01-01"},{"nctId":"NCT05669339","phase":"PHASE2","title":"AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"University of Florida","startDate":"2024-12-02","conditions":["Hepatocellular Carcinoma"],"enrollment":12,"completionDate":"2026-04"},{"nctId":"NCT07416786","phase":"NA","title":"Validation of NAD+ Measurements for Human Clinical Studies","status":"NOT_YET_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2026-04-01","conditions":["Healthy Adults"],"enrollment":48,"completionDate":"2028-07-31"},{"nctId":"NCT06627868","phase":"NA","title":"Nicotinamide Adenine Dinucleotide (NAD+) Metabolism in Human Brown Adipose Tissue","status":"RECRUITING","sponsor":"University of Turku","startDate":"2024-11-20","conditions":["Obesity, Abdominal"],"enrollment":68,"completionDate":"2027-08-31"},{"nctId":"NCT04332341","phase":"EARLY_PHASE1","title":"Study of Nicotinamide Riboside Supplementation in Allogeneic Hematopoietic Cell Transplantation","status":"RECRUITING","sponsor":"Case Comprehensive Cancer Center","startDate":"2020-05-19","conditions":["Allogeneic Hematopoietic Cell Transplantation"],"enrollment":20,"completionDate":"2026-09"},{"nctId":"NCT06032923","phase":"PHASE1,PHASE2","title":"Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2024-03-13","conditions":["Systemic Lupus Erythematosus (Sle)"],"enrollment":78,"completionDate":"2028-08-01"},{"nctId":"NCT07414212","phase":"PHASE1,PHASE2","title":"Evaluation of the Combined Therapy of EH-301 and N-acetylcysteine Together With Riluzole in Amyotrophic Lateral Sclerosis (ALS)","status":"RECRUITING","sponsor":"Biogipuzkoa Health Research Institute","startDate":"2025-11-25","conditions":["Amyotrophic Lateral Sclerosis"],"enrollment":90,"completionDate":"2027-11-25"},{"nctId":"NCT04770896","phase":"PHASE3","title":"A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-04-26","conditions":["Unresectable Hepatocellular Carcinoma"],"enrollment":557,"completionDate":"2026-06-30"},{"nctId":"NCT06227221","phase":"PHASE2","title":"Efficacy and Safety of Sorafenib in New-Onset Type 1 Diabetes Mellitus","status":"NOT_YET_RECRUITING","sponsor":"Second Xiangya Hospital of Central South University","startDate":"2026-02","conditions":["Type 1 Diabetes"],"enrollment":10,"completionDate":"2029-06"},{"nctId":"NCT05092945","phase":"NA","title":"Brown Adipose Tissue Metabolism in Type 2 Diabetes","status":"COMPLETED","sponsor":"Université de Sherbrooke","startDate":"2021-05-18","conditions":["Type 2 Diabetes"],"enrollment":6,"completionDate":"2025-08-18"},{"nctId":"NCT02143726","phase":"PHASE2","title":"Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2014-10-09","conditions":["Refractory Hurthle Cell Thyroid Cancer"],"enrollment":35,"completionDate":"2028-08-06"},{"nctId":"NCT05934409","phase":"NA","title":"Adipose Tissue Storage in the Rapid Remission of Hepatic and Cardiac Metabolic Dysfunction After Bariatric Surgery","status":"RECRUITING","sponsor":"Université de Sherbrooke","startDate":"2023-11-01","conditions":["Diabetes Mellitus Type 2"],"enrollment":40,"completionDate":"2028-05-01"},{"nctId":"NCT06843148","phase":"NA","title":"Stimulating Fat Tissue Storage With Niacin to Reduce Fat Accumulation in the Liver.","status":"RECRUITING","sponsor":"Université de Sherbrooke","startDate":"2026-04","conditions":["Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)","Liver Fibrosis/NASH","Non-Alcoholic Steato-Hepatitis (NASH)"],"enrollment":36,"completionDate":"2030-07"},{"nctId":"NCT01903694","phase":"PHASE3","title":"Randomized Trial Sorafenib-Pravastatin Versus Sorafenib Alone for the Palliative Treatment of Child-Pugh A Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2010-03","conditions":["Child-Pugh A Hepatocellular Carcinoma"],"enrollment":474,"completionDate":""},{"nctId":"NCT01275300","phase":"NA","title":"Biosynthesis of PGD2 in Vivo","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2007-07","conditions":["Hyperlipidemia"],"enrollment":9,"completionDate":"2012-01"},{"nctId":"NCT00989469","phase":"PHASE1,PHASE2","title":"Sorafenib With Irinotecan in Metastatic Colorectal Cancer (mCRC) and K-RAS Mutation","status":"COMPLETED","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2009-02","conditions":["Metastatic Colorectal Cancer"],"enrollment":64,"completionDate":"2012-02"},{"nctId":"NCT03211416","phase":"PHASE1,PHASE2","title":"Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2017-12-07","conditions":["Advanced Adult Hepatocellular Carcinoma","Child-Pugh Class A","Stage III Hepatocellular Carcinoma","Stage IIIA Hepatocellular Carcinoma","Stage IIIB Hepatocellular Carcinoma","Stage IIIC Hepatocellular Carcinoma","Stage IV Hepatocellular Carcinoma","Stage IVA Hepatocellular Carcinoma","Stage IVB Hepatocellular Carcinoma"],"enrollment":37,"completionDate":"2025-08-15"},{"nctId":"NCT06983730","phase":"EARLY_PHASE1","title":"The Kidney's Response to Exercise in Heat, and the Impact of Vitamin B3 on This Response","status":"RECRUITING","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2026-01-26","conditions":["Heat Strain","Healthy Volunteer Study","Kidney Dysfunction"],"enrollment":28,"completionDate":"2028-06"},{"nctId":"NCT01715441","phase":"PHASE2","title":"Sorafenib in Combination With Irinotecan in Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors","status":"COMPLETED","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2012-09","conditions":["Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors"],"enrollment":173,"completionDate":"2015-09"},{"nctId":"NCT07380438","phase":"NA","title":"A Clinical Study to Evaluate the Efficacy of a Nutritional Supplement to Improve Carotenoid Content as Measured by a Non-invasive Hyperspectral Absorption Device","status":"COMPLETED","sponsor":"Pharmanex","startDate":"2025-10-20","conditions":["Nutrition Assessment"],"enrollment":84,"completionDate":"2026-01-08"},{"nctId":"NCT06861088","phase":"PHASE3","title":"The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"Quercis Pharma AG","startDate":"2025-12-19","conditions":["Venous Thromboembolism","Metastatic Pancreatic Cancer","Locally Advanced Pancreatic Adenocarcinoma"],"enrollment":480,"completionDate":"2029-10-31"},{"nctId":"NCT06018467","phase":"PHASE2","title":"Senolytics to Improve Osteoporosis Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Odense University Hospital","startDate":"2023-09-06","conditions":["Osteopenia, Osteoporosis","Age-related Bone Loss"],"enrollment":120,"completionDate":"2026-04-30"},{"nctId":"NCT01730937","phase":"PHASE3","title":"Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2013-04","conditions":["Adult Primary Hepatocellular Carcinoma","Advanced Adult Primary Liver Cancer","Recurrent Adult Primary Liver Cancer"],"enrollment":193,"completionDate":"2025-09-04"},{"nctId":"NCT03164057","phase":"PHASE2","title":"A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-06-15","conditions":["Acute Myeloid Leukemia","Myelodysplastic Syndromes"],"enrollment":206,"completionDate":"2027-06"},{"nctId":"NCT04914845","phase":"PHASE1","title":"KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2021-08-27","conditions":["Acute Myeloid Leukemia","Acute Myeloid Leukemia, in Relapse","Acute Myeloid Leukemia Refractory"],"enrollment":16,"completionDate":"2025-10-22"},{"nctId":"NCT05590468","phase":"PHASE2","title":"A Study to Evaluate Vitamin B3 Derivative to Treat Mitochondrial Myopathy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ralitza Gavrilova","startDate":"2023-05-26","conditions":["Mitochondrial Myopathy"],"enrollment":34,"completionDate":"2026-11"},{"nctId":"NCT05878119","phase":"PHASE2","title":"Effects of MIB-626 With and Without A High-Intensity Multi-Dimensional Exercise Training Program","status":"COMPLETED","sponsor":"Metro International Biotech, LLC","startDate":"2023-10-25","conditions":["Healthy"],"enrollment":124,"completionDate":"2025-08-04"},{"nctId":"NCT00826540","phase":"PHASE2","title":"Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2009-09","conditions":["Recurrent Colon Cancer","Recurrent Rectal Cancer","Stage IV Colon Cancer","Stage IV Rectal Cancer"],"enrollment":83,"completionDate":"2014-02"},{"nctId":"NCT05561738","phase":"NA","title":"Nicotinamide Riboside in Ulcerative Colitis","status":"RECRUITING","sponsor":"University of Pittsburgh","startDate":"2024-02-28","conditions":["Ulcerative Colitis"],"enrollment":40,"completionDate":"2026-06-30"},{"nctId":"NCT07350538","phase":"NA","title":"The Critical Link Between Gut Microbiome Dysfunction, Cravings and Relapse: RECLAIM-GUT TRIAL","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Roehampton","startDate":"2025-12-10","conditions":["Healthy Subjects"],"enrollment":20,"completionDate":"2026-06-15"},{"nctId":"NCT07341217","phase":"NA","title":"Chemo Brain Prehab Project","status":"NOT_YET_RECRUITING","sponsor":"Dr. Chris Gaffney","startDate":"2026-01-30","conditions":["Colorectal Cancer","Older Adults (60 - 85 Years Old)","Physically Inactive","Chemotherapy"],"enrollment":86,"completionDate":"2027-09-16"},{"nctId":"NCT07271316","phase":"PHASE2","title":"Alii Supplement Study","status":"RECRUITING","sponsor":"Texas Christian University","startDate":"2026-01-12","conditions":["Nutrient Deficiency","Happiness","Digestive Health","Vulnerability to Disease","Mood Swings","Energy"],"enrollment":68,"completionDate":"2026-04-29"},{"nctId":"NCT07337486","phase":"NA","title":"\"Evaluation of a Non-Pharmacological Skin Care Intervention for the Prevention and Treatment of Skin Toxicities Caused by Immunotherapy in Cancer Patients\"","status":"COMPLETED","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2022-05-30","conditions":["Skin Toxicity in Patients on Checkpoint Inhibitors"],"enrollment":130,"completionDate":"2024-10-30"},{"nctId":"NCT04562831","phase":"NA","title":"The NO-ALS Study: A Trial of Nicotinamide/Pterostilbene Supplement in ALS.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Haukeland University Hospital","startDate":"2020-10-07","conditions":["Amyotrophic Lateral Sclerosis"],"enrollment":380,"completionDate":"2026-10-31"},{"nctId":"NCT05224336","phase":"PHASE1","title":"Psilocybin-assisted Therapy for Phantom Limb Pain","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2022-10-03","conditions":["Phantom Limb Pain"],"enrollment":10,"completionDate":"2024-03-07"},{"nctId":"NCT03685253","phase":"PHASE1,PHASE2","title":"Nicotinamide Riboside for Diabetic Neuropathy","status":"TERMINATED","sponsor":"University of Maryland, Baltimore","startDate":"2019-01-24","conditions":["Diabetic Neuropathy Peripheral"],"enrollment":10,"completionDate":"2022-05-01"},{"nctId":"NCT04677049","phase":"PHASE1,PHASE2","title":"Study of Niacin in Glioblastoma","status":"SUSPENDED","sponsor":"AHS Cancer Control Alberta","startDate":"2021-03-18","conditions":["Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype"],"enrollment":59,"completionDate":"2026-12-31"},{"nctId":"NCT05117957","phase":"PHASE2","title":"Efficacy and Safety of Sorafenib in Previously Treated Advanced Hepatocellular Carcinoma: SOPT Study","status":"COMPLETED","sponsor":"Bo Hyun Kim","startDate":"2022-03-08","conditions":["Advanced Hepatocellular Carcinoma"],"enrollment":50,"completionDate":"2025-12-18"},{"nctId":"NCT07306364","phase":"PHASE2","title":"Psilocybin-Assisted Physical Therapy in Chronic Low Back Pain","status":"NOT_YET_RECRUITING","sponsor":"Yale University","startDate":"2026-06","conditions":["Chronic Low Back Pain (CLBP)","Physical Therapy","Psilocybin"],"enrollment":45,"completionDate":"2029-06"},{"nctId":"NCT07022938","phase":"PHASE4","title":"Nutritional Supplement for Treating Chemotherapy Induced Neuropathy","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2021-11-01","conditions":["Cancer","Neuropathy","Chemotherapy Induced Pain Neuropathy","Chemotherapy-Induced Peripheral Neuropathy"],"enrollment":71,"completionDate":"2025-12-15"},{"nctId":"NCT01658878","phase":"PHASE1,PHASE2","title":"An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-10-30","conditions":["Hepatocellular Carcinoma"],"enrollment":657,"completionDate":"2024-11-12"},{"nctId":"NCT04784234","phase":"NA","title":"Vision Preservation and Restoration Following a 6 Month Trial of GlaucoCetin","status":"TERMINATED","sponsor":"Wills Eye","startDate":"2021-02-01","conditions":["Primary Open Angle Glaucoma"],"enrollment":12,"completionDate":"2022-10-27"},{"nctId":"NCT03533582","phase":"PHASE3","title":"Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2018-05-24","conditions":["Childhood Hepatocellular Carcinoma","Childhood Malignant Liver Neoplasm","Fibrolamellar Carcinoma","Hepatoblastoma","Hepatocellular Malignant Neoplasm, Not Otherwise Specified"],"enrollment":537,"completionDate":"2026-12-31"},{"nctId":"NCT07296354","phase":"PHASE4","title":"Evaluation of an ATP-Containing Parenteral Vitamin B Complex in Patients With Symptomatic Diabetic Polyneuropathy","status":"NOT_YET_RECRUITING","sponsor":"Egyptian International Pharmaceutical Industries Co","startDate":"2026-01-10","conditions":["Neuropathic Pain"],"enrollment":200,"completionDate":"2029-01-10"},{"nctId":"NCT07280637","phase":"NA","title":"Regenarative Treatment of Periocular Wrinkles With PDRN","status":"RECRUITING","sponsor":"University of Taubate","startDate":"2025-11-30","conditions":["Skin Wrinklings"],"enrollment":25,"completionDate":"2026-08-30"},{"nctId":"NCT07258667","phase":"PHASE1","title":"Pilot Study of the Efficacy of Nicotinamide (Vitamin B3) in Leber's Hereditary Optic Neuropathy","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Angers","startDate":"2026-04","conditions":["Leber Hereditary Optic Neuropathy (LHON)","Leber's Hereditary Optic Neuropathy (LHON)","Mitochondrial Disease","Optic Nerve Disease"],"enrollment":13,"completionDate":"2028-04"},{"nctId":"NCT00494182","phase":"PHASE2","title":"Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-04-25","conditions":["Metastatic Head and Neck Squamous Cell Carcinoma","Metastatic Squamous Cell Carcinoma of the Hypopharynx","Metastatic Squamous Cell Carcinoma of the Larynx","Metastatic Squamous Cell Carcinoma of the Oral Cavity","Metastatic Squamous Cell Carcinoma of the Oropharynx","Recurrent Head and Neck Squamous Cell Carcinoma","Recurrent Hypopharyngeal Squamous Cell Carcinoma","Recurrent Laryngeal Squamous Cell Carcinoma","Recurrent Oral Cavity Squamous Cell Carcinoma","Recurrent Oropharyngeal Squamous Cell Carcinoma"],"enrollment":48,"completionDate":"2026-12-31"},{"nctId":"NCT01871766","phase":"PHASE2","title":"Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-12-04","conditions":["Rhabdomyosarcoma"],"enrollment":115,"completionDate":"2030-06"},{"nctId":"NCT07284225","phase":"NA","title":"Acute Effects of Nicotinamide Riboside on Polysomnography-Measured Sleep Structure in Healthy Adults","status":"NOT_YET_RECRUITING","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2025-12-20","conditions":["Healthy Volunteers"],"enrollment":20,"completionDate":"2026-12-30"},{"nctId":"NCT07286747","phase":"PHASE2","title":"Efficacy and Safety of Oral Controlled-release Nicotinic Acid (CIR-NA) for the Remission of Prediabetes. (CONCEPT)","status":"NOT_YET_RECRUITING","sponsor":"University Hospital Schleswig-Holstein","startDate":"2026-01-01","conditions":["Prediabetes (Insulin Resistance, Impaired Glucose Tolerance)"],"enrollment":390,"completionDate":"2028-12-31"},{"nctId":"NCT04120766","phase":"PHASE2","title":"Safety and Modulation of ABCC9 Pathways by Nicorandil for the Treatment of Hippocampal Sclerosis of Aging","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gregory Jicha, MD, PhD","startDate":"2021-12-01","conditions":["Dementia","Mild Cognitive Impairment"],"enrollment":64,"completionDate":"2026-11-30"},{"nctId":"NCT03247088","phase":"PHASE1,PHASE2","title":"Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-07-30","conditions":["Recurrent Acute Myeloid Leukemia","Refractory Acute Myeloid Leukemia"],"enrollment":74,"completionDate":"2027-12-31"},{"nctId":"NCT07278492","phase":"PHASE1","title":"NAD Augmentation to Prevent or Reverse Alzheimer's Disease in People With Down Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2026-04-01","conditions":["Down Syndrome (DS)"],"enrollment":24,"completionDate":"2028-06-30"},{"nctId":"NCT03755791","phase":"PHASE3","title":"Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Exelixis","startDate":"2018-06-10","conditions":["Hepatocellular Carcinoma"],"enrollment":837,"completionDate":"2026-07-31"},{"nctId":"NCT07268339","phase":"PHASE3","title":"A Phase III Randomised Control Clinical Trial of Radiotherapy With Radiosensitisation Versus Intravesical Bacillus Calmette-Guerin Therapy for High-risk Non-muscle Invasive Bladder Cancer.","status":"NOT_YET_RECRUITING","sponsor":"The Christie NHS Foundation Trust","startDate":"2025-12-01","conditions":["High-Risk Non-Muscle Invasive Bladder Cancer"],"enrollment":328,"completionDate":"2031-12-01"},{"nctId":"NCT05194397","phase":"PHASE2","title":"Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors","status":"RECRUITING","sponsor":"Children's Hospital of Philadelphia","startDate":"2023-02-23","conditions":["Lymphoblastic Leukemia","Cancer Survivors","Aplastic Anemia","Myelodysplastic Syndromes","Myeloid Leukemia"],"enrollment":80,"completionDate":"2026-06-30"},{"nctId":"NCT07264010","phase":"PHASE2,PHASE3","title":"Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study","status":"NOT_YET_RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2025-12-01","conditions":["Acute Myeloid Leukaemia (AML)","Measurable Residual Disease (MRD)"],"enrollment":87,"completionDate":"2028-12-30"},{"nctId":"NCT05398484","phase":"PHASE2,PHASE3","title":"Psilocybin Therapy in Advanced Cancer","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2023-05-24","conditions":["Advanced Cancer"],"enrollment":200,"completionDate":"2027-01-01"},{"nctId":"NCT04844528","phase":"PHASE2","title":"Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia With History of Non-melanoma Skin Cancers","status":"RECRUITING","sponsor":"University of Utah","startDate":"2022-02-25","conditions":["Chronic Lymphocytic Leukemia","Non-melanoma Skin Cancer (NMSC)"],"enrollment":86,"completionDate":"2028-08"},{"nctId":"NCT05617508","phase":"PHASE2","title":"N-DOSE AD: A Dose Optimization Trial of Nicotinamide Riboside in Alzheimer's Disease","status":"COMPLETED","sponsor":"Haukeland University Hospital","startDate":"2022-11-22","conditions":["Alzheimer Disease","Dementia"],"enrollment":80,"completionDate":"2025-06-05"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Capsule, Shampoo, Solution, Tablet","formulations":[{"form":"CAPSULE","route":"ORAL","productName":"Vitafol Caplet"},{"form":"CAPSULE","route":"ORAL","productName":"RENO CAPS"},{"form":"CAPSULE","route":"ORAL","productName":"Concept OB"},{"form":"CAPSULE","route":"ORAL","productName":"Integra F"},{"form":"CAPSULE","route":"ORAL","productName":"Integra Plus"},{"form":"CAPSULE","route":"ORAL","productName":"MyhephronDialysis and Stress Supplement"},{"form":"CAPSULE, GELATIN COATED","route":"ORAL","productName":"Reaphirm Plant Source DHA"},{"form":"CAPSULE, GELATIN COATED","route":"ORAL","productName":"Vita-Rx Diabetic Vitamin"},{"form":"CAPSULE, GELATIN COATED","route":"ORAL","productName":"VitafolOne"},{"form":"CAPSULE, LIQUID FILLED","route":"ORAL","productName":"TriStart DHA"},{"form":"CAPSULE, LIQUID FILLED","route":"ORAL","productName":"Vitafol Plus"},{"form":"CAPSULE, LIQUID FILLED","route":"ORAL","productName":"Concept DHA"},{"form":"SHAMPOO","route":"TOPICAL","productName":"JEUNCELL Hair restorer and Hair Growth Solution"},{"form":"SOLUTION","route":"ORAL","productName":"Multi-Vitamin Fluoride Drops"},{"form":"TABLET","route":"ORAL","productName":"NIACIN"}]},"crossReferences":{"NUI":"N0000147570","MMSL":"2275","NDDF":"001052","UNII":"2679MF687A","VUID":"4019440","CHEBI":"CHEBI:15940","VANDF":"4017632","INN_ID":"373","RXNORM":"218728","UMLSCUI":"C0027996","chemblId":"CHEMBL573","ChEMBL_ID":"CHEMBL573","KEGG_DRUG":"D00049","DRUGBANK_ID":"DB00627","PDB_CHEM_ID":" NIO","PUBCHEM_CID":"938","SNOMEDCT_US":"173196005","IUPHAR_LIGAND_ID":"1588","MESH_DESCRIPTOR_UI":"D009525"},"formularyStatus":[],"originalProduct":{"form":"CAPSULE, LIQUID FILLED","route":"ORAL","company":"US Pharmaceutical Corporation","brandName":"Concept DHA","isOriginal":true,"marketingStatus":"unapproved drug other"},"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1957-","companyName":"Medpointe Pharm Hlc","relationship":"Original Developer"}],"publicationCount":12317,"therapeuticAreas":["Metabolic"],"atcClassification":{"source":"DrugCentral","atcCode":"C04AC01","allCodes":["C04AC01","C10AD02","C10AD52","C10BA01"]},"biosimilarFilings":[],"originalDeveloper":"Medpointe Pharm Hlc","recentPublications":[{"date":"2026 Mar 25","pmid":"41882411","title":"Comparative metabolome and metallomic analyses of three organs from Cistus creticus.","journal":"Planta"},{"date":"2026 Mar 24","pmid":"41872243","title":"Effect of pH on niacinamide skin permeation.","journal":"Scientific reports"},{"date":"2026 Mar 23","pmid":"41870365","title":"Structural characterization, proton conductivity and furfural catalysis of novel polyfunctional zirconium phosphonates.","journal":"Dalton transactions (Cambridge, England : 2003)"},{"date":"2026 Mar 2","pmid":"41850071","title":"Impact of various types of heat treatment on the content of selected B vitamin and their profile in goose breast meat.","journal":"Poultry science"},{"date":"2026 Dec","pmid":"41846319","title":"Metabolic characteristic changes in local tissues after high-intensity focused ultrasound treatment for uterine fibroids.","journal":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group"}],"combinationProducts":[{"brandName":"Advicor","ingredients":"lovastatin + nicotinic acid"},{"brandName":"Simcor","ingredients":"nicotinic acid + simvastatin"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"Medpointe Pharm Hlc","companyId":"medpointe-pharm-hlc","modality":"Small molecule","firstApprovalDate":"1957","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1957-07-24T00:00:00.000Z","mah":"MEDPOINTE PHARM HLC","brand_name_local":null,"application_number":""},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"1957-07-24T00:00:00.000Z","mah":"MEDPOINTE PHARM HLC","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"1957-07-24T00:00:00.000Z","mah":"MEDPOINTE PHARM HLC","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"1957-07-24T00:00:00.000Z","mah":"MEDPOINTE PHARM HLC","brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"1957-07-24T00:00:00.000Z","mah":"MEDPOINTE PHARM HLC","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"1957-07-24T00:00:00.000Z","mah":"MEDPOINTE PHARM HLC","brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T00:09:15.450566+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}